Uromigos-Bladder Cancer

The UromigosThe Uromigos | May 16, 2023
Dr. Meeks discusses expression-based subtypes for defining pathologic response to neoadjuvant ICIs in patients with MIBC.
Listen Now
The UromigosThe Uromigos | March 28, 2023
Sia Daneshmand, MD, reviews 2 studies on the use of erdafitinib for the treatment of NMIBC, including the THOR-2 trial.
The UromigosThe Uromigos | March 22, 2023
The Uromigos are joined by Kala Sridhar, MD, to discuss the PET MUSE study on the impact of PET imaging in MIUC.
The UromigosThe Uromigos | March 7, 2023
Michiel Van der Heijden, MD, PhD, joined The Uromigos to review bladder cancer research from the 2023 ASCO GU Symposium.
The UromigosThe Uromigos | February 21, 2023
Matt Galsky, MD discusses updates for the CheckMate 274 Trial at the 2023 ASCO GU Cancers Symposium with The Uromigos.
The UromigosThe Uromigos | February 18, 2023
Enrique Grande, MD, PhD, Msc, met with The Uromigos at the 2023 ASCO GU Cancers Symposium to discuss the IMvigor130 study.
The UromigosThe Uromigos | February 18, 2023
Andrea Necchi, MD describes the results of the phase 2 KEYNOTE-057 study at the 2023 ASCO GU Cancers Symposium.
The UromigosThe Uromigos | February 6, 2023
Vadim Koshkin, MD, discusses the prevalence of HER2 expression in bladder cancer and the UNITE study for advanced UC.
The UromigosThe Uromigos | January 31, 2023
Petros Grivas, MD, PhD, joins The Uromigos to discuss the use of antibody drug conjugates in bladder cancer.
The UromigosThe Uromigos | January 23, 2023
A summary of the prostate and bladder cancer session of the Conversations & Trending Topics in GU Cancers conference.
The UromigosThe Uromigos | January 9, 2023
Sam Chang, MD, MBA, joins The Uromigos to discuss the results of IL-15RαFc superagonist N-803 for papillary NMIBC.
The UromigosThe Uromigos | December 20, 2022
Is cisplatin any different from carboplatin in advanced bladder cancer? The Uromigos debate the topic with Matt Galsky, MD.
The UromigosThe Uromigos | November 28, 2022
Dr. Andrea Necchi describes his recent phase 2 study on the use of neoadjuvant pembrolizumab and nab-paclitaxel for MIBC.
The UromigosThe Uromigos | October 25, 2022
The Uromigos chat with Cora Sternberg on her paper on FGFR inhibition in advanced urothelial cancer.
The UromigosThe Uromigos | August 22, 2022
John Kelly summarizes a recent paper published in JAMA that describes the benefits of robotic surgery versus open cystectomy.
The Uromigos | August 15, 2022
Cora Sternberg, MD, discusses her career that has spanned multiple continents.
The UromigosThe Uromigos | May 9, 2022
Syed Hussain and Sam Funt describe their studies on this topic.
The UromigosThe Uromigos | March 14, 2022
Matt Galsky and Tom Powles take the FDA and EMA approach respectively concerning adjuvant nivolumab for bladder cancer.
The UromigosThe Uromigos | March 7, 2022
Cisplatin-based combination chemotherapy is considered standard of care in mUC, but many patients are deemed ineligible.
The UromigosThe Uromigos | February 18, 2022
Dr. Jonathan Rosenberg describes the results of this positive randomized phase 2 trial.
Advertisement
Advertisement